Douglas C. Throckmorton

Author

United States Food and Drug Administration

Also Known As

D C Throckmorton, D THROCKMORTON, D Throckmorton, D. C. Throckmorton, DOUGLAS THROCKMORTON, Douglas C Throckmorton, Douglas C. Throckmorton, Douglas Throckmorton

Publications

2.6K

Citations

H-Index

Concepts

All Affiliations

United States Food and Drug Administration Center for Drug Evaluation and Research Augusta University Yale University National Cancer Institute

About

Douglas C. Throckmorton is an author at United States Food and Drug Administration specializing in medicine, cell biology, and nephrology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	848
2	Health Sciences	3	3	217
3	Public Health	3	3	180
4	Social Sciences	1	1	15
5	Biomedical Engineering	1	1	174

Douglas C. Throckmorton

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium Frank Dieterle, Frank D. Sistare, Federico Goodsaid, Nature Biotechnology Translational MedicineUrologyRenal FunctionMedicineKidney Failure	2010	403
PDGF and TGF-β mediate collagen production by mesangial cells exposed to advanced glycosylation end products Douglas C. Throckmorton, Anne P. Brogden, Brian Min, Kidney International AngiogenesisMedicineGlycosylation End ProductsGlycobiologyBiomedical Engineering	1995	174
Activation-induced apoptosis in human macrophages: developmental regulation of a novel cell death pathway by macrophage colony-stimulating factor and interferon gamma. David H. Munn, Arthur C. Beall, Dongli Song, The Journal of Experimental Medicine	1995	172
Effect of US Drug Enforcement Administration’s Rescheduling of Hydrocodone Combination Analgesic Products on Opioid Analgesic Prescribing Christopher M. Jones, Peter Lurie, Douglas C. Throckmorton JAMA Internal Medicine	2016	127
Regulation of mesangial cell growth by polypeptide mitogens. Inhibitory role of transforming growth factor beta. F Jaffer, Christopher Saunders, P J Shultz, PubMed	1989	119
Scientific and Regulatory Approach to Botanical Drug Development: A U.S. FDA Perspective Charles Wu, Lee Su-Lin, Cassandra Taylor, Journal of Natural Products	2020	101
Challenges for Clinical Cannabis and Cannabinoid Research in the United States Ziva D. Cooper, Donald I. Abrams, Steven W. Gust, JNCI Monographs	2021	100
Modeling the evolution of the US opioid crisis for national policy development Tse Yang Lim, Erin J. Stringfellow, Celia Stafford, Proceedings of the National Academy of Sciences Opioid EpidemicSubstance UseDrug PolicyCrisis ManagementPolicy Analysis	2022	88
The FDA and the Next Wave of Drug Abuse — Proactive Pharmacovigilance Douglas C. Throckmorton, Scott Gottlieb, Janet Woodcock New England Journal of Medicine Opioid EpidemicSubstance UseNext WaveDrug AbuseDrug Policy	2018	73
Periodic high extracellular glucose enhances production of collagens III and IV by mesangial cells Akihiko Takeuchi, Douglas C. Throckmorton, Anne P. Brogden, American Journal of Physiology-Renal Physiology Collagens IiiMedicineExtracellular Glucose ConcentrationPhysiologyHuman Tissue	1995	56

Page 1